Molecular prevalence of Pneumocystis jirovecii and Cryptosporidium in patients with asthma.

Asthma Cryptosporidium Pneumocystis jirovecii Sputum Stool

Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 02 09 2023
revised: 23 10 2023
accepted: 25 10 2023
pubmed: 2 11 2023
medline: 2 11 2023
entrez: 1 11 2023
Statut: ppublish

Résumé

Asthma is characterized by chronic airway inflammation. In addition to allergens, microorganisms can affect the clinical course of asthma. It has been shown that some fungi play an important role in the progression of asthma. However, the effects of Pneumocystis jirovecii and Cryptosporidium spp., on the disease are little known. We investigated P. jirovecii and Cryptosporidium spp. in the sputum and stool sample of patients with asthma (n = 40) by microscopy and PCR compared to the healthy group (n = 40). P. jirovecii (12.5 %), and Cryptosporidium spp. (12.5 %) were detected in the sputum samples of only asthmatic patients (p = 0.029 and 0.029 respectively). However, Crpytosporidium spp. was detected equally in stool samples of both groups (p = 0.682). Our results indicate that P. jirovecii and Cryptosporidium spp. should be considered in patients with asthma and molecular screening of these neglected eukaryotes in respiratory tract samples may be beneficial in the clinical management of the disease.

Identifiants

pubmed: 37913698
pii: S0732-8893(23)00233-X
doi: 10.1016/j.diagmicrobio.2023.116124
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116124

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have declared no conflict of financial and non-financial interests

Auteurs

Ozlem Ulusan Bagci (O)

Department of Parasitology, Faculty of Medicine, Ege University, Izmir, Turkey; Department of Basic Oncology, Institute of Health Sciences, Ege University, Izmir, Turkey.

Ozlem Goksel (O)

Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma, Faculty of Medicine, Ege University, Izmir, Turkey; Ege University Translational Pulmonary Research Group (EGESAM), Izmir, Turkey.

Reyhan Gumusburun (R)

Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma, Faculty of Medicine, Ege University, Izmir, Turkey.

Ufuk Mert (U)

Ege University Translational Pulmonary Research Group (EGESAM), Izmir, Turkey; Ataturk Health Care Vocational School, Ege University, Izmir, Turkey.

Gulhan Bogatekin (G)

Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma, Faculty of Medicine, Ege University, Izmir, Turkey.

Seray Toz (S)

Department of Parasitology, Faculty of Medicine, Ege University, Izmir, Turkey.

Ayse Caner (A)

Department of Parasitology, Faculty of Medicine, Ege University, Izmir, Turkey; Department of Basic Oncology, Institute of Health Sciences, Ege University, Izmir, Turkey; Ege University Translational Pulmonary Research Group (EGESAM), Izmir, Turkey. Electronic address: ayse.caner@ege.edu.tr.

Classifications MeSH